Choi Joon Hyuk, Ro Jae Y
Department of Pathology, College of Medicine, Yeungnam University, Daegu 42415, Korea.
Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Medical College of Cornell University, Houston, TX 77030, USA.
Biomedicines. 2022 Jul 29;10(8):1826. doi: 10.3390/biomedicines10081826.
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver carcinoma displaying both hepatocytic and cholangiocytic differentiation within the same tumor. Relative to classic hepatocellular carcinoma (HCC), cHCC-CCA has more aggressive behavior and a poorer prognosis. Though recent advances have improved our understanding of the biology underlying cHCC-CCAs, they remain diagnostically challenging for pathologists because of their morphologic and phenotypic diversity. Accurate diagnosis of cHCC-CCA is important for patient management and prognostication. Herein, we review recent updates on cHCC-CCA, focusing on tumor classification, pathology, and diagnostic approach.
肝内胆管癌合并肝细胞癌(cHCC-CCA)是一种罕见的原发性肝癌,在同一肿瘤内同时表现出肝细胞和胆管细胞分化。相对于经典肝细胞癌(HCC),cHCC-CCA具有更具侵袭性的行为和更差的预后。尽管最近的进展增进了我们对cHCC-CCA潜在生物学特性的理解,但由于其形态学和表型的多样性,对病理学家来说,其诊断仍具有挑战性。准确诊断cHCC-CCA对患者的管理和预后评估很重要。在此,我们回顾cHCC-CCA的最新进展,重点关注肿瘤分类、病理学和诊断方法。